MilliporeSigma Webinars

81. Application Of Two-Dimensional Chromatography To Improve Productivity Of Analytical Testing Of Cell & Gene Therapy Products 10/13/2021

    Analytical characterization of cell and gene therapy products remains a challenging, costly, and time-consuming task. In this video we present a proof-of-concept work demonstrating application of multidimensional chromatography for characterization of Adenovirus type 5 (Ad5)-based product that not only allowed increased productivity, but also limits the sample volume needed for the analysis.

82. AAV Gene Therapy: Orthogonal Methods To Understand And Define CQAs 10/13/2021

    As with all biopharmaceuticals, it is important to identify and monitor the critical quality attributes (CQAs) of these products to ensure their safety and efficacy. Our experts present a range of orthogonal methods to understand and define the CQAs of AAV products.

83. Getting It Right. A Candid Conversation About Remote Viral Clearance Studies 8/19/2021

    Evolving regulatory guidelines and a global pandemic will not derail your viral clearance study timelines with Provise™ Clearance services.

84. Achieving High Yields In Scalable Xeno-Free Culture Formats With Mesenchymal Stem Cell Medium 7/27/2021

    In this webinar, we will explore the current landscape and future trends of cell culture media for adult mesenchymal stem cells and discuss the options to derive MSC’s from bone marrow in xeno-free conditions from static to microcarrier-based suspension culture platforms. Finally, we will demonstrate the Stemline^® XF MSC Media we’ve developed to reduce scalability roadblocks while maintaining robust performance.

85. Advancing Biopharm Manufacturing And Supply Chain Capabilities With An Integrated eData Solution 4/13/2021

    This webinar describes how the implementation of Pharma 4.0 technologies across the industry offers the promise and opportunity to significantly improve many aspects of Biopharma manufacturing and supply chain capabilities. eData exchange is a critical aspect of realizing the full potential of these digital solutions.

86. Which Ingredient Are You Missing In Your Gene Therapy Success Recipe? 3/25/2021

    In this podcast, Ratish Krishnan, Associate Director for Cell & Gene Therapy talks about the tremendous promise gene therapies have for changing the healthcare paradigm and solutions to some of the biggest challenges in gene therapy manufacturing.

87. Developing A Scalable Upstream Bioreactor Process For Lentiviral Vector Production In Suspension 3/8/2021

    Gene therapies hold the promise to change lives. As your path to patients accelerates, how can you assure the robust process design, intensification and scalability that meets your evolving manufacturing needs? And what benefits can a templated process bring to your commercial success? Learn the answers to these questions and more in this webinar.

88. How Biosafety Assurance Can Be Both Rapid And Purposeful 2/24/2021

    A discussion on how novel treatment modalities such as viral vectors and the urgent need for SARS-CoV-2 treatments and vaccines are driving the advance of biopharma. 

89. Effect Of Product Concentration On Continuous Parvovirus Retentive Filtration 2/23/2021

    This video illustrates how careful process development and system design can address higher-concentration intermediate challenges and optimize virus filtration processes.

90. Biosafety In Gene Therapy: Applying The Latest Regulatory Guidance For RCL Testing 2/23/2021

    The use of lentivirus vectors to produce groundbreaking gene therapies is on the rise. Ensuring the biosafety and quality of these vectors is achieved through a multi-tiered testing approach. For lentivirus-based therapies, generation of replication competent particles is a potential risk. While improvements in design and manufacturing have decreased the probability of producing replication competent viruses, regulatory agencies provide guidelines to test for their presence at multiple stages in production.